## **Core Concept**
Neuroblastoma is a type of cancer that primarily affects children and originates from immature nerve tissue. The prognosis of neuroblastoma varies widely depending on several factors, including age, stage, and genetic characteristics of the tumor. Understanding these factors is crucial for determining the best course of treatment.

## **Why the Correct Answer is Right**
The correct answer, **MYCN non-amplification**, is a well-established good prognostic factor for neuroblastoma. MYCN is an oncogene, and its amplification is associated with more aggressive disease and poorer outcomes. Tumors without MYCN amplification tend to have a better prognosis. This is because MYCN amplification leads to increased cell proliferation and inhibition of cell death, making the tumor more aggressive.

## **Why Each Wrong Option is Incorrect**
- **Option A: Chromosomal aberration**: While certain chromosomal aberrations can be associated with neuroblastoma, not all are good prognostic factors. Some, like MYCN amplification, are associated with a worse prognosis.
- **Option B: High N-myc copy number**: This is actually a poor prognostic factor. High levels of MYCN (also known as N-myc) are associated with more aggressive tumors and a worse outcome.
- **Option D: Diploidy**: Near-diploid or diploid tumors with complex karyotypes can have a worse prognosis compared to hyperdiploid tumors. The prognostic significance can vary, but in general, MYCN status and segmental chromosomal aberrations are more critical.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that **age < 18 months, MYCN non-amplification, and hyperdiploidy** are generally associated with a favorable prognosis in neuroblastoma. The INSS (International Neuroblastoma Staging System) and INES (International Neuroblastoma Risk Group Staging System) classifications take into account these factors to stratify patients into low, intermediate, or high-risk groups. ## **Correct Answer:** . MYCN non-amplification